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Abstract
Prion diseases are transmissible, progressive and invariably fatal neurodegenerative conditions associated with
misfolding and aggregation of a host-encoded cellular prion protein, PrP
C. They have occurred in a wide range of
mammalian species including human. Human prion diseases can arise sporadically, be hereditary or be acquired.
Sporadic human prion diseases include Cruetzfeldt-Jacob disease (CJD), fatal insomnia and variably protease-
sensitive prionopathy. Genetic or familial prion diseases are caused by autosomal dominantly inherited mutations
in the gene encoding for PrP
C and include familial or genetic CJD, fatal familial insomnia and Gerstmann-Sträussler-
Scheinker syndrome. Acquired human prion diseases account for only 5% of cases of human prion disease. They
include kuru, iatrogenic CJD and a new variant form of CJD that was transmitted to humans from affected cattle
via meat consumption especially brain. This review presents information on the epidemiology, etiology, clinical
assessment, neuropathology and public health concerns of human prion diseases. The role of the PrP encoding
gene (PRNP) in conferring susceptibility to human prion diseases is also discussed.
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Background
Prion diseases are transmissible protein misfolding dis-
orders in which misfolding of a host-encoded prion pro-
tein (PrP) occurs. PrP is a 253 amino acids (aa) protein.
The first 22 N-terminal aa are removed from PrP after
its transport to endoplasmic reticulum, while the last 23
C-terminal aa are cleaved off after the addition of glyco-
sylphosphatidylinositol (GPI) anchor, which helps the
protein to attach to the outer surface of cell membranes.
PrP may exist in two forms: a normal cellular prion pro-
tein designated as PrP
C and a pathogenic misfolded con-
former designated as PrP
Sc.B o t hP r P
C and PrP
Sc
conformers are encoded from the same sequence of the
16 kb single copy PRNP gene that is positioned on the
short (p) arm of human chromosome 20 (20p13), from
base pairs 4,666,796-4,682,233. The human PRNP con-
tains two exons with the second one carrying the whole
open reading frame. The abnormal PrP
Sc isoform differs
from the normal PrP
C isoform in secondary and tertiary
structure, but not in primary amino acids sequence.
PrP
C is predominantly rich in alpha helical contents,
while PrP
Sc is predominantly rich in beta sheet contents
[1-5]. This conformational discrepancy renders the
PrP
Sc isoform extremely resistant to proteolysis and
degradation by conventional means of chemical and
physical decontamination or disinfection. In contrast to
PrP
Sc,P r P
C is soluble in non-denaturing detergents and
is completely degraded by proteases [1,3].
The superscript (Sc) has been used to refer to scrapie,
the first and the most ancient animal Transmissible
Spongiform Encephalopathy (TSE). Many authors also
use superscripts other than (Sc) to distinguish normal
and pathogenic (disease-causing) isoforms. These
include (res) for resistant and (Dis) for disease. An
abbreviated name of a prion disease can also be used as
superscript to point out the origin of the pathogenic iso-
form i.e. PrP
Sc or PrP
CJD. The pathogenic conformers
are simply called prions (the infectious protein particles)
[3].
According to seeding-nucleation model, the preexist-
ing or acquired PrP
Sc oligomers catalyze the conversion
of PrP
C molecules into PrP
Sc fibrils the breakage of
which provides more PrP
Sc templates for the conversion
process. The process of prion propagation in the brain
results in the pathogenesis of prion diseases [6]. Sixteen
different variants of prion disease have been reported so
far: nine in humans and seven in animals. The etiology,
host range and year of description for these disease var-
iants are given in Table 1. In the present review, a brief
description of human prion diseases is provided.
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Sporadic Cruetzfeldt-Jacob disease accounts for 85% of
all CJD cases with annual worldwide incidence of 1-2
cases/million population [27]. It occurs equally in both
sexes with a peak age of onset between 55 and 75 years.
Some younger (below 20 years) and oldest (above 90
years) cases have also been reported. Clinical symptoms
include rapidly progressive dementia, cerebellar dysfunc-
tion including muscle incoordination, and visual, speech
and gait abnormalities. Dementia is the major symptom
followed by spontaneous or induced myoclonia. During
the disease course, symptoms of pyramidal and extra-
pyramidal dysfunction with reflexes, tremors, spasticity
and rigidity, and behavioral changes with agitation, con-
fusion and depression may also be observed. At the end
of the disease course, most of patients go into a state of
akinetic mutism (they become unresponsive to exterior
stimuli) [28,29].
The presence of spongiform changes and sparse PrP
Sc
distribution in CNS of sCJD patients are the hallmark of
neuropathology of the disease. The deposits of amyloid
plaques may also be noticed in 5-10% of cases [28,30].
On the basis of clinicopathological findings, different
variants of sCJD have been described. Amaurotic or
Heindenhain variant is characterized by rapidly progres-
sive dementia, myoclonus, visual disturbances such as
hallucinations, visual agnosia and cortical blindness, and
short disease duration; Brownell and Oppenheimer var-
iant is characterized by an early and predominant
cerebellar ataxia and relatively late dementia; the thala-
mic form is characterized by dementia and movement
disorders; while the panencephalic Japanese variant is
characterized by high amount of cells in CSF, profound
damage of the white matter and a very slow disease
course [28,29,31,32].
On the basis of clinical, biological, electrophysiological
and neuropathological findings, sCJD cases can be clas-
sified as possible, probable or definite cases. Possible
cases are characterized by rapidly progressive dementia
accompanied by at least two of the following symptoms:
myoclonus, cerebellar or visual symptoms, pyramidal or
extrapyramidal signs, akinetic mutism and disease
course of less than 2 years. Possible cases are considered
probable cases when they reveal a characteristic periodic
EEG or increased levels of 14-3-3 protein in CSF [29].
Definite cases are defined by the presence of spongiform
changes or PrP
Sc reactivity in brain. Notably, sCJD
symptoms may also be seen in disorders like Alzhei-
mer’s disease, diffuse Lewy body disease or frontal
dementia, paraneoplastic syndrome, tumor or stroke and
in disorders with toxic, nutrition, metabolism or infec-
tion-related causes. Differential diagnosis for possible
and probable cases of sCJD is, therefore, needed. Com-
puted tomography (CT) may reveal signal of mild brain
atrophy in some cases. The use of cranial magnetic reso-
nance imaging (MRI) is helpful in detecting brain atro-
phy and, in more than 50% of cases, may reveal high
signals on T2, flair or diffusion-weighted sequences in
Table 1 Etiology of prion disease
Animal prion diseases
Disease Host Etiology Year of Description References
Scrapie Sheep, Goats Infection with Prions of unknown origin Mid 18th century [7,8]
TME Mink Infection with Prions of either sheep or cattle origin 1947 [8-10]
CWD Cervids Infection with Prions of unknown origin 1967 [8,10,11]
BSE Cattle Infection with Prions of unknown origin 1986 [8,12]
EUE Nyala, Kudu Infection with Prions of BSE origin 1986 [8,10,13,14]
FSE Cats Infection with Prions of BSE origin 1990 [8,10,15]
NHP Lemurs Infection with Prions of BSE origin 1996 [8,10,16]
Human prion diseases
Disease Host Etiology Year of Description References
Kuru Human Ritualistic Cannibalism or “Transumption” 1957 [17]
sCJD Human Spontaneous PrP
C®PrP
Sc conversion or somatic mutation 1920 [18,19]
f/gCJD Human Mutations in PRNP 1924 [20]
GSS Human Mutations in PRNP 1936 [21]
iCJD Human Infection with Prions of human origin by cadaveric corneal grafts, hGH or dura mater 1974 [22]
FFI Human PRNP haplotype 178N-129M 1986 [23]
vCJD Human Infection with Prions of BSE origin 1996 [24]
sFI Human Spontaneous PrP
C®PrP
Sc conversion or somatic mutation 1999 [25]
VPSPr Human Spontaneous PrP
C®PrP
Sc conversion or somatic mutation 2008 [26]
Imran and Mahmood Virology Journal 2011, 8:559
http://www.virologyj.com/content/8/1/559
Page 2 of 9basal ganglia or in cerebral or cerebellar cortex [29].
Almost all sCJD cases show altered electroencephalo-
graphic (EEG) signals. Slow wave activity remains con-
stant and deteriorates with the progression of the
disease. Pseudo-periodic sharp wave complexes of 1
Hertz are characteristic of EEG in sCJD cases. To over-
come the transient nature of periodic sharp wave com-
plexes, repeated EEG recordings are required [29,33].
The clinicopathological and molecular phenotypes of
sCJD are greatly influenced by variations in PRNP.
PRNP polymorphisms in regulatory as well as coding
sequences have been associated with predisposition to
the disease development [34-36]. Homozygosity at
M129V polymorphism is a strong risk factor for the
development of sCJD [36,37]. In Japanese, homozygosity
at another PRNP polymorphism E219K is also a risk fac-
tor for the development of sCJD [38,39]. E219K has
been found in only Asian and Pacific populations which
are more homozygous for methionone at codon 129 as
compared to Western populations [27,40]. Inefficient
interaction between heterologous PrP
C molecules
encoded from distinct PRNP alleles (129 M and 129 V)
may restrict the conversion of PrP
C into PrP
Sc. Any con-
straint in the process of prion propagation is assumed to
slow down the progression of the disease [36]. The clini-
cal phenotypic heterogeneity seen in sCJD cases can be
attributed to different prion strains. A strain is bio-
chemically defined by pattern and ratios of PrP
Sc frag-
ments on Western blot. Three M129V genotypes (129
MM, 129 MV and 129 VV) and 2 strain types (type 1
and type 2) can be coupled into 6 combinations (MM1,
MV1, VV1, MM2, MV2 and VV2) which correspond
very well to different clinical phenotypes of sCJD. On
the basis of these 6 combinations, three different strain
classification systems have been proposed [32,41-43].
Fatal familial insomnia (FFI)
Previously known as thalamic dementia but renamed
in 1986 as fatal familial insomnia (FFI) is an autosomal
dominantly inherited human prion disease. FFI is
caused by a PRNP mutation D178N linked to methio-
nine of the PRNP polymorphism M129V. When linked
to valine at the codon 129, the same mutation leads to
a diverse phenotype of f/gCJD [23,44,45]. So far,
almost 100 cases of FFI in almost 40 families have
been reported from Italy, Germany, Austria, Spain, UK,
France, Finland, the United States, Australia, Japan,
China, and Morocco [46].
FFI occurs equally in men and women without any
significant difference between 129 MM and 129 MV
genotypes. However, the disease duration may be signifi-
cantly shorter in 129 MM subjects. The FFI cases pre-
sent between 20 and 72 years with an average of 49
y e a r sa n dm a yl i v ea f t e rt h ed i s e a s eo n s e tf o r8 - 7 2
months with an average of 18.4 months. Clinical symp-
toms include insomnia or disrupted sleep. Myoclonus,
ataxia, dysarthria, dysphagia, and pyramidal signs, and
autonomic hyperactivation can also be noted. Severity
and sequence of clinical symptoms may differ between
129 MM and 129 MV genotypes. Insomnia, myoclonus
and autonomic dysfunction are often more severe in
129 MM subjects, while ataxia, dysarthria and seizures
often predominate in 129 MV subjects [28,29,44,45,47].
Polysomnography is very useful for the diagnosis of
the disease. It provides evidence of insomnia by display-
ing marked reduction in sleep time and disorderly tran-
sition between sleep stages. The 129 MV genotype is
known to reduce the severity of these signs of abnormal
sleep. In contrast, the 129 MV genotype is associated
with more widespread hypometabolism in the thalamus
and cingulate cortex as revealed by positron emission
tomography (PET). Thus, PET may be another useful
tool for the diagnosis of FFI. With later cerebral cortical
and cerebellar involvement, neuronal loss and astroglio-
sis occur predominantly in the anterior and dorsome-
dian thalamic nuclei in all cases and in the inferior
olives in most cases with scant PrP deposition. However,
PrP deposits may be more evident in the molecular layer
of the cerebellum with a strip like pattern and in the
subiculum entorhinal region [28,29,44,45,47].
Sporadic fatal insomnia (sFI)
A sporadic form of fatal insomnia (sFI) was reported in
1999. The patients showed clinical and neuropathologi-
cal signs similar to FFI but family history and muta-
tions in PRNP were not evident. All patients were 129
MM homozygotes and biochemical strain typing of
t h e s ed i s e a s es u b t y p e sr e v e a l e dt h eo n l yd i f f e r e n c ei n
the intensity of the unglycosylated fragment of PrP
Sc
type 2; the unglycosylated fragment was under-repre-
sented in FFI [25,45,48]. So far, near 24 sFI cases all
revealing 129 MM homozygosity and propagating
PrP
Sc type 2 have been reported in various countries of
the world [49]. sFI is occasionally also referred to as
“sCJDMM2 thalamic” but is clinicopathologically suffi-
ciently distinct from sCJDMM2. In sCJDMM2, cerebral
cortex is most severely affected rather than thalamus
where possibly the circadian rhythms of sleep-wake
cycle are controlled [42,45]. How the same MM2 PrP
Sc
encodes distinct phenotypes in sCJD and sFI is a mat-
ter of concern, indicating that factors additional to the
codon 129 genotype and PrP
Sc type may also be
involved in the determination of prion strains. How-
ever, MM2 PrP
Sc conformers associated with sCJD and
sFI may show variation in the intensity and size of
their fragments by the application of more sensitive 2-
dimensional electrophoretic separation and improved
PK digestion conditions [42].
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Familial CJD (fCJD) is associated with dominantly inher-
ited point mutations in PRNP. There is a region of 5
repeats within PrP from residues 51-91 comprised of a
nonapeptide PQGGGGWGQ and four tandem octapep-
tide repeats (PHGGGWGQ)4. Insertions of 2-9 octapep-
tide repeats (2-9-OPRI) and a deletion of 2 octapeptide
repeats (2-OPRD) in PRNP are also associated with sus-
ceptibility to fCJD. Because more than 50% of fCJD
cases have been reported without a positive family his-
tory of the disease, the term “genetic CJD (gCJD)” is
now being used more frequently instead of fCJD. There
is much variation in the penetrance of different muta-
tions as evidenced by considerable intrafamilial and
intragenerational phenotypic variability; sometimes, the
disease may skip a generation. The incidence of gCJD is
5-15% of all CJD cases. Although the familial nature of
gCJD is known since 1920s, mutations associated with
the disease were first reported in 1989 only 2 years after
the cloning of PRNP cDNA [28,29,42,44,47,50]. The fre-
quency of mutations differs worldwide; however, geogra-
phical or ethnic clusters of gCJD cases with mutations
E200K, I210V, D178N, and V180I have been reported
from Israel, Slovakia, Chile, Italy, Spain and Japan
[42,51].
Similar to CJD, the clinicopathological phenotype in
gCJD largely correlates with the codon 129 genotypes
and PrP
Sc type, and mutations appear to play a role not
more than a susceptibility factor. Whether PRNP poly-
morphisms other than M129V also influence the disease
characteristics is unknown. Multiple strains, although
yet remain unidentified, may be involved in the patho-
genesis of the disease. For some gCJD cases, fragments
of 12-18.5 kDa in addition to fragments of 19 and 21
kDa which characterize PrP
Sc types 2 and 1, respectively,
can also be found. PRNP mutations may play their part
in the pathogenesis of gCJD by i) increasing the propen-
sity of PrP
C and PrP
M for aggregation, ii) increasing the
retention of aggregated PrP molecules within secretory
pathways, and iii) modulating the intramolecular salt-
bridge and hydrogen bond interactions. Disturbance in
intramolecular interactions is known to project the
hydrophobic amino acids outside making the protein
insoluble [44]. With increase of every OPR, both the
ability of PrP
M for binding divalent ions such as copper
and the severity of clinicopathological phenotype are
increased. The biochemical strain typing of gCJD often
reveals the underrepresentation of unglycosylated frag-
ments. This is because unglycosylated fragments are
more unstable than mono- and diglycosylated fragments
and are, therefore, more inefficient in their transport
from secretory pathways to the plasma membrane
[42,44,52]. Although clinical phenotypes related to most
of mutations overlap with those of sCJD [42], the
clinical phenotype in gCJD cases carrying the T183A-
129M haplotype is slightly distinctive and incorporates
personality changes followed by rapidly progressive
dementia, with fronto-temporal features such as aggres-
sive behavior, hyperorality, verbal stereotypes and often
parkinsonian signs [53].
Gerstmann-Sträussler-Scheinker syndrome (GSS)
Autosomal dominant inheritance of PRNP mutations
may also lead to another form of human TSE named as
Gerstmann-Sträussler-Scheinker Syndrome (GSS). The
incidence of GSS is 1 in 100 million of population per
year [28]. GSS is characterized by an early onset
between 30 and 60 years of age and slow disease pro-
gression extended over a period of 3.5-9.5 years. Clinical
symptoms which may show intrafamilial and intragen-
erational variation include cerebellar ataxia, gait
abnormalities, dementia, dysarthria, ocular dysmetria,
infrequent myoclonus, spastic paraparesis, parkinsonian
signs, and hyporeflexia or areflexia in the lower extremi-
ties [28,29]. However, legs hyperreflexia from an early
disease course has recently been seen in a Japanese GSS
patient carrying the P102L mutation [54]. In GSS,
altered sleep and temperature rhythms may also be
noticed [55]. The PRNP polymorphism M129V has been
shown to influence the disease phenotype. When linked
to V129 allele, P102L, which is the most common cause
of GSS, resulted in the predominance of psychiatric
s i g n ss u c ha sa p a t h ya n dd e p r ession [56]. EEG is rarely
diagnostic in GSS. Following PRNP mutations have been
shown to cosegregate with GSS: P102L, P105L, A117V,
Y145X, Q160X, F198S, Q217R, Y218N, Y226X and
Q227X [28,29,57]. Y218N demonstrated clinical criteria
for possible Alzheimer disease and possible frontotem-
poral dementia, with neurofibrillary degeneration on
neuropathological profiles, and various PrP
Sc fragments
in the range of 10-80 kDa [58]. In general, neuropatho-
logic features of GSS patients include numerous amyloid
plaques, severe to absent spongiform changes, neuronal
loss, astrocytic microgliosis, and variable nuerofibrillary
tangles [28,29,59].
Iatrogenic CJD (iCJD)
Iatrogenic CJD (iCJD) was first described in 1974 in a
person who received cadaveric corneal transplant from a
patient of CJD [22]. Several cases of human prion dis-
ease, since then, have been associated with iatrogenic
transmission of CJD by the use of stereotactic intracer-
ebral EEG needles or neurosurgical instruments, cadave-
ric dura mater grafts and intramuscular injections of
contaminated cadaveric pituitary-derived human growth
hormone (hGH) and gonadotrophin hormone. The
highest proportion of iCJD cases is attributed to treat-
ment with hGH and Lyodura grafts produced by B.
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May 1987. Most of CJD cases linked to treatment with
hGH have occurred in France, while those linked to
treatment with dura mater grafts have mainly occurred
in Japan [28,29,51,60]. Between the late 1950s and 1985,
about 30,000 children were treated with hGH world-
wide, and the overall proportion of CJD cases from the
treated population has been estimated to be about 1/
100. It is believed that the likely PrP
Sc contamination of
pituitary-derived hGH and dura mater grafts resulted
from the practice of batch processing. Before the pro-
duction of recombinant hGH, it was a pharmaceutical
practice to process 5,000-20,000 cadaveric pituitary
glands in a single batch for the extraction of the hor-
mone. The presence in the batch of a few pituitary
glands from unknown CJD cases may be responsible for
contamination. With the availability of recombinant
hGH and the initiation of separated processing of indivi-
dual dura mater grafts since 1987, the probability of
occurring future iCJD cases appears to be very low. A
peak in the incidence of iCJD cases with long incubation
periods may occur, however [28,29,60].
The clinicopathological features of CJD linked to
treatment with hGH resemble with those of kuru. The
129 MM homozygosity is a risk factor and incubation
periods may be in the range of 4.5 to over 25 years with
a mean of 12 years [28,29,60,61]. In contrast, the clini-
copathological features of CJD linked to neurografting
of dura mater or the use of neurosurgical instruments
resemble with those of sCJD. The mean duration of ill-
ness is 18 months and the incubation periods may be in
the range of 1.5-18 years with a mean of about 6 years.
In Japan, the minimum risk of developing iCJD has
been estimated to be approximately 1/3000 Lyodura
graft recipients [28,29,60].
Kuru
Kuru is the first human prion disease that was shown to
be transmissible to chimpanzees by intracerebral intro-
duction of brain homogenates from kuru patients [62].
Kuru has occurred exclusively in the Fore linguistic
group of Papua New Guinea Eastern Highlands and the
neighboring peoples with whom they intermarried.
There was a practice among these groups to consume
the dead bodies of their relatives as a mark of respect
and mourning (ritualistic cannibalism). Women and
young children of both sexes were more exposed to the
risk material such as brain and viscera than adult men
who usually had preferentially to consume muscles. The
kuru epidemic killed 1-2% of the population at its peak.
Some villages became even devoid of adult women.
With a ban on ritualistic cannibalism in the mid-1950s
imposed by Australian authorities, the incidence of the
disease started to decline steadily. Kuru was introduced
to Western medicine in late 1950s, although the first
case of kuru was observed around 1920. The Western
scientists were very soon able to prove ritualistic canni-
balism as the etiology of the disease. The older kuru
patients who experienced an exposure to the infection
before the ban can still be seen. The incubation periods
of kuru in such patients would be more than 50 years
[27,59,63-65]. Kuru has imposed strong selection pres-
sure in the affected Fore groups on PRNP especially at
codons 127 and 129. Heterozygosity at these PRNP
codons is a resistance factor for kuru and can be seen
with marked prevalence among survivors of the kuru
epidemic [27,65].
Kuru has 3 clinical stages namely ambulant (still can
walk), sedentary (only can sit up), and terminal (unable
to sit up independently). An ill-defined prodromal per-
iod characterized by headache and pain usually in the
joints of legs may precede these stages. Cerebellar ataxia,
tremors and choreiform and athetoid movements are
distinctive and prominent clinical signs. Shivering ampli-
fiable by cold was the symptom on the basis of which
the disease was named “kuru”.T h em o s tp r o m i n e n t
clinical feature of sCJD, the dementic illness can also
occur in some cases but it happens during the final dis-
ease stages only. Neuropathological features such as
spongiosis, neuronal loss, and astrocytic microgliosis can
variably be observed in CNS usually in the grey matter.
The PrP
Sc deposition is observed in CNS only [59,63].
The neuropathological property which distinguishes
kuru from sCJD is the presence of numerous kuru pla-
ques, spherical bodies with a rim of radiating filaments.
Kuru is believed to be caused by the consumption of a
sCJD case and experimental transmission studies have
shown similarity between the molecular and pathobiolo-
gical properties of prions causing kuru, sCJD and iCJD
[66]. Similar studies have also revealed differences in
transmission dynamics, peripheral pathogenesis and the
neuropathology properties of kuru and vCJD prions. As
b o t hk u r ua n dv C J Da r ec a u s e db yi n f e c t i o nv i ao r a l
route, these differences can be attributed to the strain
type rather than the route of infection [63]. However, a
recent study showed that sCJD, BSE and scrapie agents
were evidently different from the kuru agent in incuba-
tion time, brain neuropathology, and the lymphoreticu-
lar involvement. The authors concluded that “the
geographic independence of the kuru agent provides
additional reasons to explore causal environmental
pathogens in these infectious neurodegenerative dis-
eases” [67,68].
Variant CJD (vCJD)
The first 10 patients of new variant or simply of variant
CJD (nvCJD/vCJD) were reported in April 1996 in UK
[24,60]. The age of these patients was relatively younger
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minance of psychiatric symptoms instead of cerebellar
ataxia or progressive dementia [60]. About 219 vCJD
cases have been reported hitherto from 8 European and
4 non-European countries (USA, Canada, Saudi Arabia,
and Japan). The most of vCJD cases (172) have been
reported from UK alone [69]. Psychiatric and behavioral
symptoms of vCJD may include agitation, aggression,
depression, anxiety, apathy, emotional lability, insomnia,
poor concentration, paranoid delusion, recklessness, or
withdrawal; a combination of two or more of these
symptoms appears in most of the patients. Some
patients may also show signs of sensory disturbance
such as pain, paresthesia, and dysesthesia. The neurolo-
gic symptoms occur at least 6 months after the onset of
psychiatric symptoms and include cerebellar ataxia, cog-
nitive impairment, involuntary movements which may
be dystonic, choreiform or myoclonic. Incontinence of
urine, progressive immobility, and akinetic mutism are
the late onset signs. Death often occurs because of inter-
current infections. The mean age at onset of symptoms
is 29 years, and the progression or total duration of the
disease spans 18 months in average, which is similar to
that is reported for kuru and iCJD linked to treatment
with hGH [28,29,60]. Generalized slowing of EEG activ-
ity and an increase in the levels of 14-3-3 protein in
CSF may be diagnostic of vCJD in more than 50% of the
cases. However, the observation of posterior thalamic
high signals characterized by ‘pulvinar’ or ‘hockey stick’
signs on T2 diffusion or Flair weighted MRI imaging
and the detection of PrP
res in tonsillar biopsy are impor-
tant for the specific diagnosis of the disease [29,70].
The neuropathalogical hallmark of vCJD is the pre-
sence of kuru-type amyloid plaques surrounded by
spongiform lesions “the florid plaques” which also have
been seen in scrapie but never in other human prion
diseases [28,29,60]. Spongiform changes occur most evi-
dently in the basal ganglia and thalamus with sparse dis-
tribution throughout the cerebral cortex. The florid
plaques and PrP
res immunohistochemical staining have
occurred predominantly in the cerebellum and cerebrum
[28]. However, sufficient amounts of PrP
res are detected
in the lymphoreticular system of vCJD patients [60].
The detection of PrP
res in the lymphoreticular system
has confidently been used for the diagnosis of vCJD
even in clinically normal subjects (carriers) [71]. To
date, all vCJD patients have been 129 MM homozygotes
[72].
Very soon after the report on 10 vCJD cases, epide-
miological studies, experimental transmission of the dis-
ease to cynomologous macaques and mice (wild as well
as transgenic) and biochemical strain typing linked the
etiology of vCJD to infection from BSE prions [60]. The
same or diverse phenotypes may develop on primary
and secondary transmission of vCJD and BSE to mice
expressing human PrP, depending on the source of
inoculum and the PrP sequence of the recipient, and the
129 MV heterozygotes may be less resistant to vCJD
transmission as compared to BSE transmission [73,74].
The E219K heterozygosity which has been considered a
risk factor for transmission of BSE to humans may con-
fer resistance to vCJD transmission within humans
[70,75]. Moreover, at least 4 pathologically confirmed
cases including 1 with subclinical or potentially preclini-
cal infection have been associated with the secondary
vCJD transmission via blood transfusion [76]. These
reports on secondary iatrogenic transmission and the
possibility of vCJD occurrence with long incubation per-
iods in individuals with 129 MV and 129 VV PrP geno-
types have raised serious public health concerns
[71,72,77,78]. Some cases of kuru and iCJD have
occurred after incubating the disease for almost 50 and
30 years, respectively [63,64,76,79].
Variably protease-sensitive prionopathy (VPSPr)
In 2008, a novel form of atypical dementia was demon-
strated in 11 patients, all of whom were 129 VV homo-
zygotes and most of whom revealed a positive family
history for cognitive impairment. No mutation in PRNP
additional to the M129V polymorphism was detected.
The clinical course of the disease was 2 years longer
than sCJD but neuropathological profiles were diagnos-
tic of TSEs. A more distinctive feature based on which
the disease was named initially as “protease-sensitive
prionopathy” (PSPr) was the reduced resistance of PrP
Dis
isoforms to proteolysis by PK. The proteolysis of PrP
Dis
isoforms by PK resulted in more than 3 PrP
Dis frag-
ments. Amplification by PMCA and transmissibility to
animal models of PrP
Dis yet remain to be investigated
[26,42]. These studies will also inform on molecular
mechanisms of the disease pathogenesis.
Similar to sCJD, PSPr can be seen in individuals har-
boring any of 3 M129V genotypes (129 MM, 129 MV
and 129 VV). As the sensitivity of PrP
Dis isoforms to
treatment with PK was variable according to the codon
129 genotype, the disease was renamed as “variably pro-
tease-sensitive prionopathy” (VPSPr). The PrP
Dis from
129 VV cases was more sensitive to PK treatment than
was PrP
Dis from 129 MM cases, with PrP
Dis from 129
MV cases showing intermediary PK sensitivity [80].
Moreover, based on the codon 129 genotype, the PrP
Dis
conformers from VPSPr cases not only showed differen-
tial immunoreativity to monoclonal antibodies raised
against various PrP epitopes but also varied in the inten-
sity (ratios) of individual fragments. Whether the codon
129 genotypes are associated with distinct clinical phe-
notypes, neuropathological lesions and histological dis-
tribution of PrP
Dis remains to be elucidated. To date, 30
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and 3 of 129 MM PRNP genotype have been reported
from various countries [42,80-82]. According to this
data, the PRNP genotype 129 MM appears protective
against the development of VPSPr [42].
Conclusion
The epidemics of kuru, iatrogenic CJD and vCJD have
reached their end [83]. However, sporadic and genetic
cases of human prion diseases are occurring worldwide
with an annual prevalence of 1-2 cases per million of
population. Among genetic human prion diseases, GSS
presents predominantly as an amyloidopathy. There is
no cure for these disorders. Most of developing coun-
tries including Pakistan have no epidemiological infor-
mation on human prion diseases. We have recently
performed the analysis of PRNP in 909 unrelated Pakis-
tani individuals. An insertion of 3 octapeptide repeats
(3-OPRI) was found in heterozygous state in an indivi-
dual and the extent of homozygosity at the 129 codon
was 63%. These results indicate that Pakistani popula-
tion is susceptible to prion disorders [84]. The octapep-
tide repeats region of human PRNP consists of 5
repeats which are designated as R1 through R5. If any
nucleotide variation is found within a repeat, the name
of that nucleotide is added to the name of correspond-
ing repeat i.e., R2a or R3g [85]. A 3-OPRI (R1, R2, R2,
R3g, R2, R2, R3, R4) linked to 219 K allele in one per-
son (68 years old) and to 129 V allele in another (69
years old) has been associated with f/gCJD [86,87]. A 3-
OPRI (R1, R2, R2, R2a, R2, R2, R3, R4) linked to 129 M
allele has also been detected in a clinically normal Chi-
nese young girl and her mother who was in her late
30’s [85].
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